Skin Toxicity Clinical Trial
Official title:
Evaluation of Topical Corticosteroids Potency in Combination Preparations in Healthy Volunteers
Several combination topical drugs are available on the market. The potency of corticosteroids
depends on a particular molecular structure and the skin penetration properties. Besides
molecular structure, a penetration of a corticosteroid molecule correlates with physical
properties of the vehicle which depend on physical properties of the vehicle constituents.
Vasoconstriction assay is considered as the gold standard for testing potency of topical
corticosteroids.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | April 2019 |
Est. primary completion date | March 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - No prior history of internal diseases that required vaccine-suppressing treatments - Absence of an active skin disease. Exclusion Criteria: - Treatment with topical corticosteroids in the 4 weeks prior to the study - Immune-suppressive treatment in the 4 weeks prior to the study - Pregnancy or breast feeding |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ben-Gurion University of the Negev | Soroka University Medical Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vasoconstriction Index (VI) measured by Skin Color Reflectometry | VI change following application topical corticosteroids that are incorporated with an antibiotic and/or antifungal drugs. | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04929834 -
Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities
|
N/A | |
Completed |
NCT04929847 -
Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities
|
N/A | |
Completed |
NCT01976481 -
Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27
|
N/A | |
Completed |
NCT03448731 -
Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)
|
Phase 2 | |
Recruiting |
NCT05109858 -
Skin Toxicity by Oncological Therapies
|
||
Completed |
NCT00871429 -
Skin Care for Cancer Patients: A Product Satisfaction Survey
|
N/A | |
Recruiting |
NCT04469075 -
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
|
Phase 2 | |
Recruiting |
NCT04650256 -
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
|
N/A | |
Terminated |
NCT01317433 -
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
|
N/A | |
Active, not recruiting |
NCT03167268 -
Panitumumab Skin Toxicity Prevention Trial
|
Phase 2 | |
Recruiting |
NCT06118047 -
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
|
Phase 2 |